← Back to Search

Monoclonal Antibodies

Tiragolumab for Non-Hodgkin's Lymphoma

Phase 1

Waitlist Available

Research Sponsored by Genentech, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

Study Summary

This trial is testing a new immunotherapy drug to see if it's safe and works well against certain blood cancers.

Eligible Conditions

Non-Hodgkin's Lymphoma
Multiple Myeloma
B-Cell Lymphoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percentage of Participants With Adverse Events

Secondary outcome measures

ORR for R/R NHL

Objective Response Rate (ORR) for R/R MM

Percentage of Participants With ADAs to Atezolizumab

+3 more

Trial Design

5Treatment groups

Experimental Treatment

Group I: Arm E: Tiragolumab + Atezolizumab + Daratumumab R/R MMExperimental Treatment3 Interventions

Participants with R/R MM will receive 600 mg tiragolumab Q3W + atezolizumab by IV infusion Q3W + daratumumab by SC injection.

Group II: Arm D: Tiragolumab + Rituximab R/R NHLExperimental Treatment2 Interventions

Participants with R/R NHL will receive 600 mg tiragolumab Q3W + rituximab by IV infusion and SC injection (optional).

Group III: Arm C: Tiragolumab + Daratumumab R/R MMExperimental Treatment2 Interventions

Participants with R/R MM will receive 600 mg tiragolumab Q3W + daratumumab by subcutaneous (SC) injection.

Group IV: Arm B: Tiragolumab R/R NHLExperimental Treatment1 Intervention

Participants with relapsed or refractory (R/R) non-Hodgkin Lymphoma (NHL) will receive a single dose of 600 mg tiragolumab by IV infusion Q3W.

Group V: Arm A: Tiragolumab R/R MMExperimental Treatment1 Intervention

Participants with relapsed or refractory (R/R) Multiple Myeloma (MM) will receive a single dose of 600 mg tiragolumab by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Tiragolumab

2020

Completed Phase 2

~350

Rituximab

1999

Completed Phase 4

~1880

Atezolizumab

2017

Completed Phase 3

~5860

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Genentech, Inc.Lead Sponsor

1,539 Previous Clinical Trials

567,648 Total Patients Enrolled

Clinical TrialsStudy DirectorHoffmann-La Roche

2,199 Previous Clinical Trials

888,461 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are eligible to join this clinical trial?

"Correct. Clinicaltrials.gov indicates that the research was first published on July 22, 2019 and recently updated November 22, 2022. The trial is presently seeking 60 volunteers to be recruited across 7 sites."

Answered by AI

Is there a call for participants in this research endeavor?

"Aye, the details provided on clinicaltrials.gov appear to show that this medical trial is still accepting applicants. It was initiated on July 22nd 2019 and updated as recently as November 22nd 2022, with a total of 60 participants being recruited across 7 different research sites."

Answered by AI

Has Tiragolumab been accorded official clearance by the FDA?

"Due to limited data regarding its safety and efficacy, tiragolumab has been given a score of 1 on our scale. This is typical for phase 1 clinical trials."

Answered by AI

Have other research endeavors implemented Tiragolumab?

"Tiragolumab's first trial was conducted at the National Institutes of Health Clinical Centre in 1993. Since then, 959 trials have been completed and a further 905 are still recruiting participants, with Nashville, Tennessee being one of their main sites for research."

Answered by AI

Where are the most prominent locales for this trial in Canada?

"Patients may be enrolled in this medical study at SCRI located in Nashville, Tennessee; Oncology Hematology Care Inc. (OHC) of Cincinnati, Ohio; Colorado Blood Cancer Institute (CBCI), which is part of Presbyterian/ St. Luke's Medical Center situated in Denver and seven other sites across the country."

Answered by AI

What conditions can Tiragolumab be employed to alleviate?

"Tiragolumab is frequently prescribed for chronic lymphocytic leukemia, but also has the potential to help patients who have not responded well to tnf antagonist therapies or had a suboptimal response from prior systemic treatments such as chemotherapy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

2019. "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04045028.